Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Critical Care
Volume 2013, Article ID 383125, 2 pages
Case Report

Ketamine Infusion Associated with Improved Neurology in a Patient with NMDA Receptor Encephalitis

1Western General Hospital, Crewe Road South, Edinburgh EH4 2XU, UK
2University of Edinburgh Medical School, 47 Little France Crescent, Edinburgh EH16 4TJ, UK

Received 12 June 2013; Accepted 22 July 2013

Academic Editors: C. Diez, M. Egi, C. Mammina, A. J. Reddy, and K. S. Waxman

Copyright © 2013 Michael MacMahon et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Dalmau, E. Tüzün, H.-Y. Wu et al., “Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma,” Annals of Neurology, vol. 61, no. 1, pp. 25–36, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. J. Dalmau, A. J. Gleichman, E. G. Hughes et al., “Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies,” The Lancet Neurology, vol. 7, no. 12, pp. 1091–1098, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. M. J. Titulaer, L. McCracken, I. Gabilondo et al., “Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study,” The Lancet Neurology, vol. 12, no. 2, pp. 157–165, 2013. View at Publisher · View at Google Scholar
  4. G. Davies, S. R. Irani, C. Coltart et al., “Anti-N-methyl-D-aspartate receptor antibodies: a potentially treatable cause of encephalitis in the intensive care unit,” Critical Care Medicine, vol. 38, no. 2, pp. 679–682, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. J. Burgdorf, X. Zhang, K. L. Nicholson et al., “GLYX-13, a NMDA receptor glycine-site functional partial agonist, induces antidepressant-like effects without ketamine-like side effects,” Neuropsychopharmacology, vol. 38, no. 5, pp. 729–742, 2012. View at Publisher · View at Google Scholar